Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 42 Small Cell Lung Carcinoma 19 Breast Neoplasms 16 Sarcoma 12 Lung Neoplasms 9 Esophageal Squamous Cell Carcinoma 7 Carcinoma, Hepatocellular 7 Thyroid Neoplasms 6 Stomach Neoplasms 6 Nasopharyngeal Carcinoma 6 Esophageal Neoplasms 6 Ovarian Neoplasms 5 NSCLC 5 Carcinoma 5 Triple Negative Breast Neoplasms 4 Pheochromocytoma 4 Pancreatic Neoplasms 4 Neoplasm Metastasis 4 Colorectal Neoplasms 4 Carcinoma, Ovarian Epithelial 4 Recurrence 3 Paraganglioma 3 Neoplasms 3 Glioma 3 Cholangiocarcinoma 3 Brain Neoplasms 3 Biliary Tract Neoplasms 3 Uterine Cervical Neoplasms 2 Urogenital Neoplasms 2 Platinum-resistant Ovarian Cancer 2

Interventions

anlotinib 1 Chemotherapy, Adjuvant 1 Angiogenesis Inhibitors 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Stereotactic Body Radiation Therapy × anlotinib × Clear all

NCT04912128 2021-06-03

AnloSBRT

Peking University Third Hospital

Stereotactic Body Radiation Therapy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡